Triple
T6003735
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Loxo Oncology |
E133655
|
entity |
| Predicate | secondMajorProductMarketedName |
P68642
|
FINISHED |
| Object |
Retevmo
Retevmo is a targeted cancer therapy (selpercatinib) used to treat tumors driven by RET gene alterations, including certain lung and thyroid cancers.
|
E561040
|
NE FINISHED |
Provenance (7 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69c00872444c8190bfaf1739dcec765c |
elicitation | completed |
| NER | batch_69c04f0f63148190826198281dce3713 |
ner | completed |
| NED1 | batch_69c1088f5c84819094e4696c24c4dd79 |
ned_source_triple | completed |
| NED2 | batch_69c10a2ffdcc8190bfeebc59d98b2b29 |
ned_description | completed |
| NEDg | batch_69c1099f00f88190a5f1f0fafbb679c2 |
nedg | completed |
| PD | batch_69c049e3316c819087ea635fa7ee8472 |
pd | completed |
| PDg | batch_69c04e8c5bfc8190b986a7071d1b23e3 |
pdg | completed |
Created at: March 22, 2026, 4:06 p.m.